This statistic functions tool runs Linear Regression Slope function and companion studies for Cardlytics. Signals here center on statistical functions describing dispersion and variability alongside volatility and performance references.Provide Time Period to run the technical study.
The output start index for this execution was thirty-five with a total number of output elements of twenty-six. The Linear Regression Slope is the rate of change in Cardlytics price series over its benchmark or peer price series.
Cardlytics Technical Analysis Modules
Most technical analysis of Cardlytics help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Cardlytics from various momentum indicators to cycle indicators. When you analyze Cardlytics charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
Cardlytics, Inc. operates an advertising platform in the United States and the United Kingdom. The company was incorporated in 2008 and is headquartered in Atlanta, Georgia. Cardlytics operates under Advertising Agencies classification in the United States and is traded on NASDAQ Exchange. It employs 710 people. This overview emphasizes how Cardlytics compares to peers on valuation quality and operating consistency. Current metrics include P/B of 1.58, profit margin of -44.36%. Cardlytics has a market cap of 37.15 M, ROE of -3.26%.
Methodology
Unless otherwise specified, financial data for Cardlytics is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Cardlytics (USA Stocks:CDLX) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Inputs are aggregated from public filings and market reference sources and public institutions such as U.S. Securities and Exchange Commission (SEC) via EDGAR. Certain values may not reflect real-time changes. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Cardlytics may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Tracking Cardlytics inside a portfolio is useful because individual winners can still weaken diversification or distort overall risk targets. A disciplined tracking process turns performance data into better decisions instead of more noise.
Generate Optimal Portfolios
Align your risk and return expectations
By capturing risk tolerance and investment horizon, Macroaxis optimization evaluates acceptable risk for target return profiles. The process summarizes how much risk can be taken for a given return goal.
A comprehensive view of Cardlytics starts with financial statements and ratio context. Key ratios help frame profitability, efficiency, and growth context for Cardlytics Stock. Key reports that frame Cardlytics Stock are listed below:
Cardlytics has a market cap of 37.15 M, operating margin of -9.87%, ROE of -3.26%. Review Trending Equities for broader portfolio context. This reflects a position in Cardlytics in the portfolio view. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Our How to Invest in Cardlytics guide provides practical guidance on trading Cardlytics Stock.Analysis related to Cardlytics should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Quarterly Earnings Growth
-0.57
Earnings Share
-1.95
Revenue Per Share
4.392
Quarterly Revenue Growth
-0.24
Return On Assets
-0.09
Understanding Cardlytics includes distinguishing between market value and book value, where book value reflects Cardlytics's accounting equity. Cardlytics' market capitalization is 37.15 M. A P/B ratio of 1.58 indicates the market values Cardlytics above its accounting book value. Enterprise value stands at 203.87 M. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Valuation methods compare these perspectives to frame context.
It is useful to distinguish Cardlytics' value from its trading price, which are computed with different methods. For Cardlytics, key inputs include a P/B ratio of 1.58, a profit margin of -44.36%, ROE of -3.26%, and revenue of 233.27 M. By contrast, market price reflects the level where buyers and sellers transact.